公司資料
Zevra 股價、新聞與催化劑
- 股票代碼:
- ZVRA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
11.87 USD (-0.17%)
收盤價
最後更新: 2026年8月21日
643M USD
市值
股價為何變動
The latest monitored company update is “Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
公司概覽
Rare-Disease Commercial Platform
Zevra Therapeutics is a commercial-stage company focused on therapies for rare diseases. Its operating model combines direct commercialization, global patient-access programs and development of treatments for small, underserved populations.
MIPLYFFA
MIPLYFFA, or arimoclomol, is FDA approved with miglustat for neurological manifestations of Niemann-Pick disease type C in patients two years and older. Zevra also operates a global expanded-access program and has submitted a European marketing application.
OLPRUVA
OLPRUVA is an approved formulation of sodium phenylbutyrate for certain urea-cycle disorders, giving Zevra a second commercial product in inherited metabolic disease.
Celiprolol
Celiprolol is an investigational treatment for vascular Ehlers-Danlos syndrome. The event-driven Phase 3 DiSCOVER trial is being conducted under an FDA Special Protocol Assessment.
未來催化劑
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。